Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription

Articles published in Blood

Retrieve available abstracts of 573 articles:
HTML format

Single Articles

    July 2021
  1. ADVANI RH, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
    Blood. 2021;138:213-220.
    PubMed     Abstract available

  2. TROTMAN J, Pettitt AR
    Is it time for PET-guided therapy in follicular lymphoma.
    Blood. 2021 Jul 14. pii: 476386. doi: 10.1182/blood.2020008243.
    PubMed     Abstract available

  3. HERRERA A, Cheng A, Mimitou EP, Seffens A, et al
    Multimodal single-cell analysis of cutaneous T cell lymphoma reveals distinct sub-clonal tissue-dependent signatures.
    Blood. 2021 Jul 7. pii: 476325. doi: 10.1182/blood.2020009346.
    PubMed     Abstract available

  4. ELUARD B, Nuan-Aliman S, Faumont N, Collares D, et al
    The alternative RelB NF-kappaB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 7. pii: 476326. doi: 10.1182/blood.2020010039.
    PubMed     Abstract available

    June 2021
  5. BALSAS P, Veloza L, Clot G, Sureda-Gomez M, et al
    SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma.
    Blood. 2021 Jun 29. pii: 476270. doi: 10.1182/blood.2020010527.
    PubMed     Abstract available

  6. GHIONE P, Gu JJ, Attwood K, Torka P, et al
    Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies.
    Blood. 2021 Jun 29. pii: 476275. doi: 10.1182/blood.2021012443.

  7. REJESKI K, Perez Perez A, Sesques P, Hoster E, et al
    CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
    Blood. 2021 Jun 24. pii: 476241. doi: 10.1182/blood.2020010543.
    PubMed     Abstract available

    Mantle cell lymphoma continues to surprise, and inform!
    Blood. 2021;137:3158-3160.

  9. KORONA B, Korona D, Zhao W, Wotherspoon A, et al
    GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma.
    Blood. 2021 Jun 4. pii: 476070. doi: 10.1182/blood.2020010495.
    PubMed     Abstract available

  10. CAI J, Qing X
    Splenic marginal zone lymphoma with increased prolymphocytes.
    Blood. 2021;137:3150.

    May 2021
  11. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.

  12. PLAKS V, Rossi JM, Chou J, Wang L, et al
    CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
    Blood. 2021 May 27. pii: 476038. doi: 10.1182/blood.2021010930.
    PubMed     Abstract available

  13. SOUSSAIN C, Malaise D, Cassoux N
    Primary vitreoretinal lymphoma: A diagnostic and management challenge.
    Blood. 2021 May 25. pii: 476013. doi: 10.1182/blood.2020008235.
    PubMed     Abstract available

  14. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed     Abstract available

    A new warhead in lymphoma therapy?
    Blood. 2021;137:2568-2570.

  16. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    PubMed     Abstract available

  17. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available

  18. ZHAO Y, Wang E
    An effusion-based presentation of ALK- anaplastic large cell lymphoma.
    Blood. 2021;137:2563.

    April 2021
  19. EPPERLA N, Herrera AF
    How we incorporate novel agents into the treatment of classic Hodgkin lymphoma.
    Blood. 2021 Apr 22. pii: 475828. doi: 10.1182/blood.2020007900.
    PubMed     Abstract available

  20. BLOMBERY P, Lade S
    Defining double-hit lymphoma in the clinic.
    Blood. 2021;137:2132-2133.

  21. ADVANI R, Moskowitz AJ, Bartlett NL, Vose J, et al
    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
    Blood. 2021 Apr 7. pii: 475691. doi: 10.1182/blood.2020009178.
    PubMed     Abstract available

  22. Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.
    Blood. 2021;137:1844.

  23. CHIHARA D, Dores G, Flowers C, Morton LM, et al
    The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
    Blood. 2021 Apr 1. pii: 475679. doi: 10.1182/blood.2020010497.
    PubMed     Abstract available

    March 2021
  24. ADVANI R, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project.
    Blood. 2021 Mar 30. pii: 475653. doi: 10.1182/blood.2020010387.
    PubMed     Abstract available

  25. GUPTA M, Burns E, Georgantas NZ, Thierauf J, et al
    A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma.
    Blood. 2021 Mar 18. pii: 475579. doi: 10.1182/blood.2020010137.
    PubMed     Abstract available

  26. Subsequent neoplasms in pediatric Hodgkin lymphoma.
    Blood. 2021;137:1562.

  27. PATRIARCA A, Gaidano G
    Intravascular lymphoma: from vessels to genes.
    Blood. 2021;137:1438-1439.

    Protect our children: Hodgkin lymphoma survivors.
    Blood. 2021;137:1433-1434.

  29. ROSCHEWSKI M, Phelan JD
    Sorting biologic subtypes of primary CNS lymphoma.
    Blood. 2021;137:1436-1437.

  30. HAEBE SE, Shree T, Sathe A, Day G, et al
    Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.
    Blood. 2021 Mar 16. pii: 475531. doi: 10.1182/blood.2020009855.
    PubMed     Abstract available

  31. TIAN XP, Ma SY, Young KH, Ong CK, et al
    A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma.
    Blood. 2021 Mar 16. pii: 475529. doi: 10.1182/blood.2020010637.
    PubMed     Abstract available

    PD-1 blockade for untreated Hodgkin lymphoma.
    Blood. 2021;137:1271-1272.

  33. ELADL E, Chang H
    Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
    Blood. 2021;137:1268.

  34. PIGNARRE A, Chatonnet F, Caron G, Haas M, et al
    Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.
    Blood. 2021;137:1166-1180.
    PubMed     Abstract available

    February 2021
    CNS relapse in DLBCL: a calculable risk?
    Blood. 2021;137:1011-1012.

  36. TRUJILLO JA, Godfrey J, Hu Y, Huang J, et al
    Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
    Blood. 2021 Feb 24. pii: 475347. doi: 10.1182/blood.2020009148.

  37. DUMONTET E, Pangault C, Roulois D, Desoteux M, et al
    Extracellular vesicles shed by follicular lymphoma B cells promote the polarization of bone marrow stromal cell niche.
    Blood. 2021 Feb 24. pii: 475345. doi: 10.1182/blood.2020008791.
    PubMed     Abstract available

    Building on BTK inhibition in MCL.
    Blood. 2021;137:861-862.

  39. WIRTH A, Mikhaeel NG
    PET response-guided radiotherapy for advanced DLBCL?
    Blood. 2021;137:866-867.

  40. RULAND J
    Synergy of MALT1 and mTOR inhibition in DLBCL.
    Blood. 2021;137:724-725.

  41. MORSCHHAUSER F, Feugier P, Flinn IW, Gasiorowski R, et al
    A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Blood. 2021;137:600-609.
    PubMed     Abstract available

  42. VITOLO U, Novo M
    Bcl-2 inhibition in DLBCL: "the times they are a-changing"?
    Blood. 2021;137:577-579.

  43. CASULO C
    Checkpoint blockade in FL: eluding the king.
    Blood. 2021;137:581-582.

  44. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  45. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available

  46. DAHER M, Basar R, Gokdemir E, Baran N, et al
    Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
    Blood. 2021;137:624-636.
    PubMed     Abstract available

  47. STRATI P, Ahmed S, Furqan F, Fayad LE, et al
    Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
    Blood. 2021 Feb 3. pii: 475147. doi: 10.1182/blood.2020008865.
    PubMed     Abstract available

    January 2021
  48. THURNER L, Fadle N, Bittenbring JT, Regitz E, et al
    LRPAP1-autoantibodies in mantle cell lymphoma are associated with superior outcome.
    Blood. 2021 Jan 29. pii: 475090. doi: 10.1182/blood.2020008835.
    PubMed     Abstract available

  49. ABEYKOON JP, Wu X, Nowakowski KE, Dasari S, et al
    Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Blood. 2021;137:513-523.
    PubMed     Abstract available

  50. BOLEN CR, Mattiello F, Herold M, Hiddemann W, et al
    Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
    Blood. 2021 Jan 25. pii: 475041. doi: 10.1182/blood.2020008119.

    The balancing act in Burkitt lymphoma.
    Blood. 2021;137:289-291.

  52. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available

  53. JAIN MD, Zhao H, Wang X, Atkins R, et al
    Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma.
    Blood. 2021 Jan 15. pii: 474963. doi: 10.1182/blood.2020007445.
    PubMed     Abstract available

  54. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.

  55. ISSA D, Seefat RL, Visser O, Zweegman S, et al
    Primary therapy and survival in patients with Burkitt lymphoma in the Netherlands: a population-based study, 1989-2018.
    Blood. 2021 Jan 14. pii: 474957. doi: 10.1182/blood.2020009552.

  56. DOMOSTEGUI A, Peddigari S, Mercer CA, Iannizzotto F, et al
    Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
    Blood. 2021 Jan 14. pii: 474958. doi: 10.1182/blood.2020007452.
    PubMed     Abstract available

    Stage I DLBCL: extranodal may mean extra radiation.
    Blood. 2021;137:3-5.

    December 2020
  58. KHANLARI M, Medeiros LJ
    ALK+ large B-cell lymphoma with aberrant expression of CD3.
    Blood. 2020;136:3086.

  59. SHIMADA K, Yoshida K, Suzuki Y, Iriyama C, et al
    Frequent Genetic Alterations in Immune Checkpoint-Related Genes in Intravascular Large B-Cell Lymphoma.
    Blood. 2020 Dec 24. pii: 474768. doi: 10.1182/blood.2020007245.
    PubMed     Abstract available

    Distract NK cell killing: give them a fatty meal.
    Blood. 2020;136:2969-2970.

  61. FUKUMOTO K, Sakata-Yanagimoto M, Fujisawa M, Sakamoto T, et al
    VAV1 mutations contribute to development of T-cell neoplasms in mice.
    Blood. 2020;136:3018-3032.
    PubMed     Abstract available

  62. BAIRD JH, Frank MJ, Craig J, Patel S, et al
    CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
    Blood. 2020 Dec 18. pii: 474751. doi: 10.1182/blood.2020009432.
    PubMed     Abstract available

  63. DE LEVAL L
    Chromosomes in breast lymphoma.
    Blood. 2020;136:2848-2849.

  64. LOS-DE VRIES GT, de Boer M, van Dijk E, Stathi P, et al
    Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma.
    Blood. 2020;136:2927-2932.
    PubMed     Abstract available

  65. YOUNES S, Natkunam Y
    Elusive sentinels at the Hodgkin checkpoint.
    Blood. 2020;136:2841-2842.

  66. GIULINO-ROTH L, Pei Q, Buxton A, Bush R, et al
    Subsequent malignant neoplasms among children with Hodgkin lymphoma: A report from the Children's Oncology Group.
    Blood. 2020 Dec 11. pii: 474601. doi: 10.1182/blood.2020007225.
    PubMed     Abstract available

  67. ELNAIR R, Lunning MA
    Checkpoint inhibition in ENKTL: Kno_le_ge G_ps.
    Blood. 2020;136:2721-2722.

    Can PET eradicate irradiation in PMBCL?
    Blood. 2020;136:2725-2726.

  69. FOWLER N
    BCL-2 inhibition in follicular lymphoma: can we tip the scales?
    Blood. 2020;136:2598-2600.

    November 2020
  70. LIU H, Audino AN
    Metastatic nasopharyngeal carcinoma mimicking nodular sclerosis Hodgkin lymphoma.
    Blood. 2020;136:2596.

  71. ELLIN F, Savage KJ
    Is the CNS-PINK the new CNS risk model in ENKTL?
    Blood. 2020;136:2486-2487.

  72. HAMADANI M, Radford J, Carlo-Stella C, Caimi PF, et al
    Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Blood. 2020 Nov 19. pii: 474210. doi: 10.1182/blood.2020007512.
    PubMed     Abstract available

    Hodgkin lymphoma: outsmarting HRS cells.
    Blood. 2020;136:2362-2364.

  74. STEIDL C
    Architecture and interior design of Hodgkin lymphoma.
    Blood. 2020;136:2367-2369.

  75. YANG H, Green MR
    Harnessing lymphoma epigenetics to improve therapies.
    Blood. 2020 Nov 18. pii: 474151. doi: 10.1182/blood.2020006908.
    PubMed     Abstract available

  76. GANDHI MK, Hoang T, Law SC, Brosda S, et al
    EBV-tissue positive primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
    Blood. 2020 Nov 17. pii: 474186. doi: 10.1182/blood.2020008520.
    PubMed     Abstract available

  77. LE GOUILL S, Morschhauser F, Chiron D, Bouabdallah K, et al
    Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial.
    Blood. 2020 Nov 12. pii: 474141. doi: 10.1182/blood.2020008727.
    PubMed     Abstract available

  78. VENTURUTTI L, Melnick AM
    The dangers of deja vu: memory B cells as the cells of origin of ABC-DLBCLs.
    Blood. 2020;136:2263-2274.
    PubMed     Abstract available

  79. GANG M, Marin ND, Wong P, Neal CC, et al
    CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Blood. 2020;136:2308-2318.
    PubMed     Abstract available

  80. CROMBIE JL, LaCasce AS
    The treatment of Burkitt lymphoma in adults.
    Blood. 2020 Nov 10. pii: 474125. doi: 10.1182/blood.2019004099.
    PubMed     Abstract available

  81. SPIEGEL JY, Dahiya S, Jain MD, Tamaresis JS, et al
    Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.
    Blood. 2020 Nov 6. pii: 474111. doi: 10.1182/blood.2020006245.

  82. KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
    Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
    Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
    PubMed     Abstract available

  83. VERGE V, Soufan R
    COVID-19-induced atypical pulmonary lymphocytes.
    Blood. 2020;136:2241.

    October 2020
  84. REINKE S, Brockelmann PJ, Iaccarino I, Garcia-Marquez MA, et al
    Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Blood. 2020 Oct 28. pii: 469788. doi: 10.1182/blood.2020008553.
    PubMed     Abstract available

  85. COOK LB, Phillips AA
    How I treat Adult T-cell leukemia/lymphoma.
    Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
    PubMed     Abstract available

  86. FARHAT H, Ghanem H
    Primary cutaneous gammadelta T-cell lymphoma with secondary lung involvement.
    Blood. 2020;136:1892.

  87. HU G, Feldman AL
    Drivers of crizotinib resistance in ALK+ ALCL.
    Blood. 2020;136:1573-1575.

    NextGen CARs: the race is on.
    Blood. 2020;136:1570-1571.

    September 2020
  89. ALLEN PB, Savas H, Evens AM, Advani R, et al
    Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.
    Blood. 2020 Sep 29. pii: 463993. doi: 10.1182/blood.2020007400.
    PubMed     Abstract available

  90. TWA DDW, Lee DG, Tan KL, Slack GW, et al
    Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma (DLBCL).
    Blood. 2020 Sep 23. pii: 463849. doi: 10.1182/blood.2020006338.

  91. SARKOZY C, Hung SS, Chavez EA, Duns G, et al
    Mutational Landscape of Grey Zone Lymphoma.
    Blood. 2020 Sep 22. pii: 463845. doi: 10.1182/blood.2020007507.
    PubMed     Abstract available

  92. MORSCHHAUSER F, Feugier P, Flinn IW, Gasiorowski R, et al
    A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
    Blood. 2020 Sep 21. pii: 463804. doi: 10.1182/blood.2020006578.
    PubMed     Abstract available

  93. SANDER B
    Under the cover of mantle cell lymphoma.
    Blood. 2020;136:1378-1379.

  94. STRATI P, Jain P, Johnson RJ, Forbes SG, et al
    Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma.
    Blood. 2020 Sep 15. pii: 463764. doi: 10.1182/blood.2020007994.

  95. ESTEVE-PUIG R, Climent F, Pineyro D, Domingo-Domenech E, et al
    Epigenetic Loss of m1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma Targets Collagen Conferring Poor Clinical Outcome.
    Blood. 2020 Sep 11. pii: 463753. doi: 10.1182/blood.2020005823.

    Myc matters in HIV-associated lymphoma.
    Blood. 2020;136:1217-1218.

  97. LOS-DE VRIES GT, De Boer M, van Dijk E, Stathi P, et al
    Chromosome 20 loss is characteristic for Breast implant-Associated Anaplastic Large Cell Lymphoma.
    Blood. 2020 Sep 8. pii: 463711. doi: 10.1182/blood.2020005372.
    PubMed     Abstract available

  98. RABOSO-GALLEGO J, Casado-Garcia A, Jiang X, Isidro-Hernandez M, et al
    Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.
    Blood. 2020 Sep 6. pii: 464123. doi: 10.1182/blood.2020004996.
    PubMed     Abstract available

  99. ORTUNO FJ, Amigo ML
    Triple-hit lymphoma with hyperbasophilic Burkitt-like morphology and solely bone marrow/leukemic phase presentation.
    Blood. 2020;136:1212.

  100. EICHENAUER DA, Engert A
    How I treat nodular lymphocyte-predominant Hodgkin Lymphoma.
    Blood. 2020 Sep 2. pii: 463607. doi: 10.1182/blood.2019004044.
    PubMed     Abstract available

  101. OLLILA TA, Kurt H, Waroich J, Vatkevich J, et al
    Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.
    Blood. 2020 Sep 2. pii: 463609. doi: 10.1182/blood.2020007236.

  102. FREEMAN CL, Savage KJ, Villa D, Scott DW, et al
    Long-Term Results of PET-Guided Radiation in Advanced-Stage Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
    Blood. 2020 Sep 1. pii: 463600. doi: 10.1182/blood.2020005846.
    PubMed     Abstract available

  103. GRIFFIN GK, Weirather JL, Roemer M, Lipschitz M, et al
    Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.
    Blood. 2020 Sep 1. pii: 463601. doi: 10.1182/blood.2020006464.
    PubMed     Abstract available

    August 2020
  104. ARMAND P, Janssens AM, Gritti G, Radford J, et al
    Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Blood. 2020 Aug 31. pii: 463592. doi: 10.1182/blood.2019004753.
    PubMed     Abstract available

  105. WANG HY, Tzachanis D
    Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
    Blood. 2020;136:1112.

  106. ZHANG Q, Casanova JL
    Human TET2 bridges cancer and immunity.
    Blood. 2020;136:1018-1019.

  107. Long-term limited-stage follicular lymphoma study.
    Blood. 2020;136:1013.

  108. KOBAYASHI T, Lam PY, Jiang H, Bednarska K, et al
    Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment.
    Blood. 2020 Aug 20. pii: 463339. doi: 10.1182/blood.2020005602.
    PubMed     Abstract available

  109. DUNLEAVY K, McLintock C
    How I Treat Lymphoma in Pregnancy.
    Blood. 2020 Aug 13. pii: 463256. doi: 10.1182/blood.2019000961.
    PubMed     Abstract available

  110. ZINZANI PL, Flinn IW, Yuen SLS, Topp MS, et al
    Venetoclax-rituximab +/- bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO.
    Blood. 2020 Aug 12. pii: 461787. doi: 10.1182/blood.2020005588.
    PubMed     Abstract available

  111. FONTAN GABAS L, Goldstein RL, Casalena G, Durant M, et al
    Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL.
    Blood. 2020 Aug 12. pii: 461786. doi: 10.1182/blood.2019004713.
    PubMed     Abstract available

  112. KIM SJ, Lim JQ, Laurensia Y, Cho J, et al
    Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
    Blood. 2020 Aug 7. pii: 461762. doi: 10.1182/blood.2020007247.
    PubMed     Abstract available

  113. GRANAI M, Lazzi S
    Early pattern of large B-cell lymphoma with IRF4 rearrangement.
    Blood. 2020;136:769.

    HOIP for targeting diffuse large B-cell lymphoma.
    Blood. 2020;136:646-647.

  115. JO T, Nishikori M, Kogure Y, Arima H, et al
    LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.
    Blood. 2020;136:684-697.
    PubMed     Abstract available

  116. PRO B, Allen PB, Behdad A
    Hepatosplenic T-cell lymphoma: A rare but challenging entity.
    Blood. 2020 Aug 5. pii: 461707. doi: 10.1182/blood.2019004118.
    PubMed     Abstract available

    July 2020
  117. BARTLETT NL, Herrera AF, Domingo-Domenech E, Mehta A, et al
    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2020 Jul 30. pii: 461621. doi: 10.1182/blood.2019004701.
    PubMed     Abstract available

  118. BOBILLO S, Joffe E, Lavery JA, Sermer D, et al
    Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.
    Blood. 2020 Jul 30. pii: 461623. doi: 10.1182/blood.2020005112.
    PubMed     Abstract available

  119. ALBERT MH, Hauck F
    EBV-triggered hemophagocytic lymphohistiocytosis in a boy with a history of non-Hodgkin lymphoma.
    Blood. 2020;136:644.

  120. WEIGERT O
    The different flavors and splices of MCL.
    Blood. 2020;136:526-527.

  121. EVENS AM, Danilov AV, Jagadeesh D, Sperling AL, et al
    Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.
    Blood. 2020 Jul 14. pii: 461327. doi: 10.1182/blood.2020006926.
    PubMed     Abstract available

  122. Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175-3183.
    Blood. 2020;136:259.

  123. FRIEDRICH C, Barreau S
    A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
    Blood. 2020;136:148.

  124. LURAIN K, Uldrick TS, Ramaswami R, Polizzotto M, et al
    Treatment of HIV-associated Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate.
    Blood. 2020 Jul 1. pii: 461242. doi: 10.1182/blood.2020006048.

    June 2020
  125. HAYDEN A, Tonseth P, Lee DG, Villa D, et al
    Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach.
    Blood. 2020 Jun 30. pii: 461229. doi: 10.1182/blood.2019004296.
    PubMed     Abstract available

  126. VELDMAN J, Visser L, Huberts-Kregel M, Muller N, et al
    Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.
    Blood. 2020 Jun 26. pii: 461197. doi: 10.1182/blood.2020005546.
    PubMed     Abstract available

  127. LINDHOLM KE, Ewalt MD
    Hemophagocytic syndrome-associated intravascular large B-cell lymphoma.
    Blood. 2020;135:2432.

    NLP Hodgkin lymphoma: can we get away with less?
    Blood. 2020;135:2329-2330.

  129. NADEU F, Martin-Garcia D, Clot G, Diaz-Navarro A, et al
    Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes.
    Blood. 2020 Jun 25. pii: 461130. doi: 10.1182/blood.2020005289.
    PubMed     Abstract available

  130. KIM H, Jeong H, Yamaguchi M, Sohn I, et al
    Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
    Blood. 2020 Jun 25. pii: 461129. doi: 10.1182/blood.2020005026.
    PubMed     Abstract available

  131. PROKOPH N, Probst NA, Lee LC, Monahan JM, et al
    IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma.
    Blood. 2020 Jun 23. pii: 461097. doi: 10.1182/blood.2019003793.
    PubMed     Abstract available

  132. TONG C, Zhang Y, Liu Y, Ji X, et al
    Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma.
    Blood. 2020 Jun 18. pii: 461029. doi: 10.1182/blood.2020005278.
    PubMed     Abstract available

  133. MEIGNAN M, Gallamini A
    DeltaSUVmax for interim PET in DLBCL: old is new.
    Blood. 2020;135:2202-2203.

  134. ZHANG Q, Orlando E, Wang H, Bogusz AM, et al
    Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome.
    Blood. 2020 Jun 9. pii: 460737. doi: 10.1182/blood.2020005123.

  135. CHEN J, Goyal N, Dai L, Lin Z, et al
    Developing new ceramide analogs and identifying novel sphingolipid controlled genes against a virus-associated lymphoma.
    Blood. 2020 Jun 9. pii: 460736. doi: 10.1182/blood.2020005569.
    PubMed     Abstract available

  136. STREMENOVA SPEGAROVA J, Lawless D, Mohamad SMB, Engelhardt KR, et al
    Germline TET2 Loss-Of-Function Causes Childhood Immunodeficiency And Lymphoma.
    Blood. 2020 Jun 9. pii: 460739. doi: 10.1182/blood.2020005844.
    PubMed     Abstract available

  137. LINK BK
    Foreseeing what is to happen in DLBCL.
    Blood. 2020;135:2014-2015.

  138. BISHOP MR
    The benefit of CAR T cells in older patients.
    Blood. 2020;135:2020-2021.

  139. RATNER L
    Predicting the future: adult T-cell leukemia.
    Blood. 2020;135:2013-2014.

    May 2020
  140. ESKELUND CW, Husby S, Favero F, Klausen TW, et al
    Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
    Blood. 2020;135:2000-2004.

  141. DE BOER M, Hauptmann M, Hijmering NJ, van Noesel CJM, et al
    Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
    Blood. 2020 May 26. pii: 457298. doi: 10.1182/blood.2019004498.

  142. GAYDOSIK AM, Queen DS, Trager MH, Akilov OE, et al
    Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
    Blood. 2020 May 21. pii: 456039. doi: 10.1182/blood.2019004725.
    PubMed     Abstract available

  143. MCGINNIS E, Farinha P
    Intravascular large B-cell lymphoma presenting with acute encephalopathy.
    Blood. 2020;135:1916.

  144. HESLOP HE
    Sensitizing Burkitt lymphoma to EBV-CTLs.
    Blood. 2020;135:1822-1823.

  145. YAHALOM J, Dabaja BS, Ricardi U, Ng A, et al
    ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.
    Blood. 2020;135:1829-1832.
    PubMed     Abstract available

  146. DALTON T, Doubrovina E, Pankov D, Reynolds R, et al
    Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.
    Blood. 2020;135:1870-1881.
    PubMed     Abstract available

  147. RAMOS JC, Sparano JA, Chadburn A, Reid EG, et al
    Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial).
    Blood. 2020 May 19. pii: 456029. doi: 10.1182/blood.2019003959.
    PubMed     Abstract available

  148. JELINEK T, Zuchnicka J
    Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Blood. 2020;135:1816.

  149. MORIN RD, Scott DW
    DLBCL subclassification: divide and conquer?
    Blood. 2020;135:1722-1724.

  150. LACY SE, Barrans SL, Beer PA, Painter D, et al
    Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
    Blood. 2020;135:1759-1771.
    PubMed     Abstract available

  151. GERBY B, Hoang T
    A targetable cue in T-cell malignancy.
    Blood. 2020;135:1616-1617.

    April 2020
  152. LIAPIS K, Paterakis G
    Circulating angioimmunoblastic T-cell lymphoma cells.
    Blood. 2020;135:1607.

  153. SWENSON S, Gilbreath T, Vahle HE, Hynes-Smith RW, et al
    E3 Ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells.
    Blood. 2020 Apr 23. pii: 454471. doi: 10.1182/blood.2019002102.
    PubMed     Abstract available

  154. Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528-1532.
    Blood. 2020;135:1507.

    Go with the flow: simplified MRD in LMIC ALL.
    Blood. 2020;135:1414-1415.

  156. ZHANG W, Yang J, Zhou C, Hu B, et al
    Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.
    Blood. 2020 Apr 22. pii: 454449. doi: 10.1182/blood.2019002008.

  157. LO A, Campbell BA, Pickles T, Aquino-Parsons C, et al
    Long-Term Outcomes for Patients With Limited-Stage Follicular Lymphoma: Update of a Population-based Study.
    Blood. 2020 Apr 22. pii: 454451. doi: 10.1182/blood.2019004588.

  158. CHESON BD
    Predicting the future for DLBCL.
    Blood. 2020;135:1308-1309.

  159. MELANI C, Jaffe ES, Wilson WH
    Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.
    Blood. 2020;135:1344-1352.
    PubMed     Abstract available

  160. VERCELLINO L, Cottereau AS, Casasnovas O, Tilly H, et al
    High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
    Blood. 2020;135:1396-1405.
    PubMed     Abstract available

    Hotter is not more aggressive: baseline SUVmax in FL.
    Blood. 2020;135:1191-1192.

  162. ALDERUCCIO JP, Isrow D, Reis IM, Iyer SG, et al
    Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?
    Blood. 2020;135:1299-1302.

  163. KRISHNAMURTHY K, Sriganeshan V
    Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric Castleman disease.
    Blood. 2020;135:1190.

  164. SIMKINS A, Dunleavy K
    Tackling Burkitt when it's back.
    Blood. 2020;135:1078-1080.

  165. FLOWERS C, Leonard JP, Fowler N
    Lenalidomide in follicular lymphoma.
    Blood. 2020 Apr 1. pii: 454206. doi: 10.1182/blood.2019001751.
    PubMed     Abstract available

    March 2020
  166. JANZ S
    MYC needs MNT to drive B cells over the edge.
    Blood. 2020;135:977-978.

  167. NGUYEN HV, Vandenberg CJ, Ng AP, Robati MR, et al
    Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Blood. 2020;135:1019-1031.
    PubMed     Abstract available

  168. RISUENO A, Hagner PR, Towfic F, Fontanillo C, et al
    Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
    Blood. 2020;135:1008-1018.
    PubMed     Abstract available

  169. CARPIO C, Bouabdallah R, Ysebaert L, Sancho JM, et al
    Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
    Blood. 2020;135:996-1007.
    PubMed     Abstract available

  170. BINKLEY MS, Rauf MS, Milgrom SA, Pinnix CC, et al
    Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.
    Blood. 2020 Mar 25. pii: 452773. doi: 10.1182/blood.2019003877.
    PubMed     Abstract available

  171. MATNANI R, Weissmann D
    Hyperdiploid B-lymphoblastic leukemia/lymphoma with hypereosinophilia and very few circulating lymphoblasts.
    Blood. 2020;135:974.

  172. CHIANG MY
    Tearing ATL apart to find HTLV's sinister plans.
    Blood. 2020;135:887-889.

  173. NEELAPU SS, Jacobson CA, Oluwole OO, Munoz J, et al
    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
    Blood. 2020 Mar 16. pii: 452706. doi: 10.1182/blood.2019004162.

  174. RUPPERT AS, Dixon JG, Salles GA, Wall A, et al
    International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.
    Blood. 2020 Mar 13. pii: 452696. doi: 10.1182/blood.2019002729.
    PubMed     Abstract available

  175. SCHODER H, Polley MY, Knopp MV, Hall NC, et al
    Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.
    Blood. 2020 Mar 13. pii: 452697. doi: 10.1182/blood.2019003277.
    PubMed     Abstract available

  176. SCHOONEN L, Weerkamp F
    CD45-negative follicular lymphoma.
    Blood. 2020;135:879.

    Sugar-coated BCR kept during FL clonal evolution.
    Blood. 2020;135:784-785.

  178. SROUR SA, Singh H, McCarty J, de Groot E, et al
    Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
    Blood. 2020;135:862-865.

  179. FU CL, Diacovo MJ
    Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen.
    Blood. 2020;135:778.

  180. PARARAJALINGAM P, Coyle KM, Arthur S, Thomas N, et al
    Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing.
    Blood. 2020 Mar 5. pii: 452635. doi: 10.1182/blood.2019002385.
    PubMed     Abstract available

  181. ROWAN AG, Dillon R, Witkover A, Melamed A, et al
    Evolution of retrovirus-infected premalignant T-cell clones prior to Adult T-cell leukemia/lymphoma diagnosis.
    Blood. 2020 Mar 5. pii: 452636. doi: 10.1182/blood.2019002665.
    PubMed     Abstract available

  182. DIEHL LF
    The efficacy-toxicity conundrum: breaking the mold.
    Blood. 2020;135:704-706.

  183. BARON M, Belin L, Cassoux N, Fardeau C, et al
    Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma.
    Blood. 2020 Mar 2. pii: 452607. doi: 10.1182/blood.2019003073.

    February 2020
  184. MESCAM L, Camus V, Schiano JM, Adelaide J, et al
    EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas.
    Blood. 2020 Feb 28. pii: 452601. doi: 10.1182/blood.2019003408.

  185. KARUBE K, Feldman AL
    "Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative.
    Blood. 2020;135:700.

  186. DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
    Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
    Blood. 2020;135:597-609.
    PubMed     Abstract available

  187. Immune landscapes in lymphoma.
    Blood. 2020;135:590.

  188. DE SMEDT R, Morscio J, Reunes L, Roels J, et al
    Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
    Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
    PubMed     Abstract available

    January 2020
  189. SONIGO G, Battistella M, Beylot-Barry M, Ingen-Housz-Oro S, et al
    HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma.
    Blood. 2020 Jan 31. pii: 440986. doi: 10.1182/blood.2019003811.

  190. LAURENT C, Nicolae A, Laurent C, Le Bras F, et al
    Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
    Blood. 2020;135:360-370.
    PubMed     Abstract available

  191. WONG R, Tan TK, Amanda S, Ngoc PCT, et al
    Feed-forward Regulatory Loop Driven by IRF4 and NF-kappaB in Adult T-cell Leukemia/Lymphoma.
    Blood. 2020 Jan 23. pii: 431345. doi: 10.1182/blood.2019002639.
    PubMed     Abstract available

  192. BASSET M, Defrancesco I, Milani P, Nuvolone M, et al
    Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
    Blood. 2020;135:293-296.

  193. WOESSMANN W, Zimmermann M, Meinhardt A, Mueller S, et al
    Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy.
    Blood. 2020 Jan 21. pii: 431277. doi: 10.1182/blood.2019003591.
    PubMed     Abstract available

  194. MIR F, Barrington S, Brown H, Nielsen T, et al
    Baseline SUVmax did not predict histological transformation in the phase 3 GALLIUM study in follicular lymphoma.
    Blood. 2020 Jan 21. pii: 431272. doi: 10.1182/blood.2019001091.
    PubMed     Abstract available

  195. STRAUS DJ, Dlugosz-Danecka M, Alekseev S, Illes A, et al
    Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Blood. 2020 Jan 16. pii: 431031. doi: 10.1182/blood.2019003127.
    PubMed     Abstract available

  196. STAIGER AM, Hoster E, Jurinovic V, Winter S, et al
    Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
    Blood. 2020;135:181-190.
    PubMed     Abstract available

  197. DURANDY A, Kracker S
    Increased activation of PI3 kinase-delta predisposes to B cell lymphoma.
    Blood. 2020 Jan 15. pii: 431027. doi: 10.1182/blood.2019002072.
    PubMed     Abstract available

  198. ODABASHIAN M, Carlotti E, Araf S, Okosun J, et al
    IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution.
    Blood. 2020 Jan 13. pii: 430246. doi: 10.1182/blood.2019002279.
    PubMed     Abstract available

    A role for NFAT signaling in ABC-DLBCL.
    Blood. 2020;135:81.

  200. XIU Y, Dong Q, Fu L, Bossler A, et al
    Coactivation of NF-kappaB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.
    Blood. 2020;135:108-120.
    PubMed     Abstract available

  201. ALDOSS I, Forman SJ
    How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 3. pii: 430058. doi: 10.1182/blood.2019002132.
    PubMed     Abstract available

    December 2019
  202. CRISTINO AS, Nourse J, West RA, Sabdia MB, et al
    EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
    Blood. 2019;134:2261-2270.
    PubMed     Abstract available

  203. ZHU H, Blum R, Bjordahl R, Gaidarova S, et al
    Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity.
    Blood. 2019 Dec 19. pii: 429991. doi: 10.1182/blood.2019000621.
    PubMed     Abstract available

  204. CHENG J, Jaffe ES
    Constipated plasma cells in extranodal marginal zone lymphoma of the lung.
    Blood. 2019;134:2226.

  205. CARBONE A, Gloghini A
    Subclassifying peripheral T-cell lymphoma NOS.
    Blood. 2019;134:2120-2121.

  206. JOHNSON WT, Mishra A
    The EZ-riding NK/T-cell lymphoma.
    Blood. 2019;134:1999-2000.

  207. BUCHER P, Erdmann T, Grondona P, Xu W, et al
    Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
    Blood. 2019 Dec 3. pii: 429231. doi: 10.1182/blood.2019001866.
    PubMed     Abstract available

  208. KLINE J, Godfrey J, Ansell SM
    The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma.
    Blood. 2019 Dec 2. pii: 429214. doi: 10.1182/blood.2019000847.
    PubMed     Abstract available

    November 2019
    Common variable immune deficiency: case studies.
    Blood. 2019;134:1787-1795.
    PubMed     Abstract available

  210. CHONG EA, Levine BL, Grupp SA, Davis MM, et al
    CAR T cell viability release testing and clinical outcomes: is there a lower limit?
    Blood. 2019;134:1873-1875.

  211. DEBACKERE K, van der Krogt JA, Tousseyn T, Finalet Ferreiro JA, et al
    FER and FES tyrosine kinase fusions in follicular T-cell lymphoma.
    Blood. 2019 Nov 20. pii: 428835. doi: 10.1182/blood.2019002401.

  212. RAMIS-ZALDIVAR JE, Gonzalez-Farre B, Balague O, Celis V, et al
    IRF4-rearranged Large B-cell lymphoma (LBCL) has a genomic profile distinct to other LBCL in children and young adults.
    Blood. 2019 Nov 18. pii: 428814. doi: 10.1182/blood.2019002699.
    PubMed     Abstract available

  213. TEACHEY DT, O'Connor D
    How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children.
    Blood. 2019 Nov 18. pii: 428813. doi: 10.1182/blood.2019001557.
    PubMed     Abstract available

  214. HUANG X, Li Z
    HIV-associated ALK- anaplastic large cell lymphoma in a young patient with small bowel intussusception.
    Blood. 2019;134:1776.

  215. JOFFE E, Kumar A, Zheng S, Uppal M, et al
    Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution.
    Blood. 2019;134.
    PubMed     Abstract available

  216. TAM CS, Siddiqi T, Allan JN, Kipps TJ, et al
    Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.
    Blood. 2019;134.
    PubMed     Abstract available

  217. SARKOZY C, Hung S, Takata K, Chavez E, et al
    Mutational Landscape of Grey Zone Lymphoma.
    Blood. 2019;134.
    PubMed     Abstract available

  218. BAI B, Vodak D, Nakken S, Wise JF, et al
    Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma.
    Blood. 2019;134.
    PubMed     Abstract available

  219. SCHUSTER SJ, Bartlett NL, Assouline S, Yoon SS, et al
    Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.
    Blood. 2019;134.
    PubMed     Abstract available

  220. LI X, Kositsky R, Reddy A, Love C, et al
    Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.
    Blood. 2019;134.
    PubMed     Abstract available

  221. KLAIRMONT MM, Gradowski JF
    Hiding in the mantle: mantle cell lymphoma with a mantle zone growth pattern co-occurring with CMV lymphadenitis.
    Blood. 2019;134:1683.

    October 2019
  222. SOMEKH I, Thian M, Medgyesi D, Gulez N, et al
    CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.
    Blood. 2019;134:1510-1516.
    PubMed     Abstract available

  223. TUEUR G, Lazarian G
    A rare case of leukemic anaplastic large cell lymphoma with the variant translocation t(X;2).
    Blood. 2019;134:1480.

  224. O'CONNOR OA
    Nurturing a diet rich in PTCL.
    Blood. 2019;134:1367-1368.

    A sobering "check" on immune checkpoint inhibitors.
    Blood. 2019;134:1366-1367.

  226. WEINSTOCK DM, Horwitz SM
    TFH lymphomas: the times they aza-changin'?
    Blood. 2019;134:1364-1365.

  227. O'CONNOR OA, Falchi L, Lue JK, Marchi E, et al
    Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
    Blood. 2019;134:1395-1405.
    PubMed     Abstract available

  228. JAIN S, Van Scoyk A, Morgan EA, Matthews A, et al
    Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas.
    Blood. 2019;134:1430-1440.
    PubMed     Abstract available

  229. Outcomes of concurrent DLBCL and indolent lymphoma.
    Blood. 2019;134:1361.

  230. WILCOX RA
    ECP in the spotLIGHT.
    Blood. 2019;134:1275-1277.

  231. KAHL BS
    An iatrogenic orphan?
    Blood. 2019;134:1273-1274.

  232. WRIGHT KT, Pozdnyakova O
    Say hello to TUGSE!
    Blood. 2019;134:1360.

  233. GAO C, McCormack C, van der Weyden C, Goh MS, et al
    Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome.
    Blood. 2019;134:1346-1350.
    PubMed     Abstract available

    PET-adapted treatment of Hodgkin lymphoma.
    Blood. 2019;134:1200-1201.

  235. PATEL SS, Weirather JL, Lipschitz M, Lako A, et al
    The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative.
    Blood. 2019 Oct 10. pii: 375148. doi: 10.1182/blood.2019002206.
    PubMed     Abstract available

  236. ANSELL SM
    Pembrolizumab: living up to expectations.
    Blood. 2019;134:1114-1115.

    September 2019
  237. AMADOR C, Greiner TC, Heavican TB, Smith LM, et al
    Reproducing the Molecular Subclassification of Peripheral T-cell Lymphoma-NOS by Immunohistochemistry.
    Blood. 2019 Sep 27. pii: blood.2019000779. doi: 10.1182/blood.2019000779.
    PubMed     Abstract available

  238. SUKSWAI N, Thirabanjasak D
    B-lymphoblastic leukemia/lymphoma with an unusual appendiceal involvement.
    Blood. 2019;134:1110.

  239. PANEA RI, Love CL, Shingleton JR, Reddy A, et al
    The whole genome landscape of Burkitt lymphoma subtypes.
    Blood. 2019 Sep 26. pii: blood.2019001880. doi: 10.1182/blood.2019001880.
    PubMed     Abstract available

  240. LUNNING M, Vose J, Nastoupil L, Fowler N, et al
    Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Blood. 2019 Sep 26. pii: blood.2019002118. doi: 10.1182/blood.2019002118.
    PubMed     Abstract available

    Antibiotics can improve CTCL.
    Blood. 2019;134:1000-1001.

  242. GOY A, Ramchandren R, Ghosh N, Munoz J, et al
    Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Blood. 2019;134:1024-1036.
    PubMed     Abstract available

  243. PATEL K, Danilov A, Pagel JM
    Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.
    Blood. 2019 Sep 25. pii: blood.2019001795. doi: 10.1182/blood.2019001795.
    PubMed     Abstract available

  244. KHATRI SS, Kim AS
    Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma.
    Blood. 2019;134:993.

  245. HILTON LK, Tang J, Ben-Neriah S, Alcaide M, et al
    --The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
    Blood. 2019 Sep 16. pii: blood.2019002600. doi: 10.1182/blood.2019002600.
    PubMed     Abstract available

  246. IYER A, Hennessey D, O'Keefe S, Patterson J, et al
    Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma.
    Blood. 2019 Sep 12. pii: blood.2019002516. doi: 10.1182/blood.2019002516.
    PubMed     Abstract available

  247. Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204.
    Blood. 2019;134:908.

  248. RAMOS CA
    The CNS can be a safe space for CARs.
    Blood. 2019;134:845-846.

  249. TAM CS, Trotman J, Opat S, Burger JA, et al
    Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
    Blood. 2019;134:851-859.
    PubMed     Abstract available

  250. ALI ND, Bains A
    Triple hit B-cell lymphoma with diffuse kidney involvement sparing the glomeruli.
    Blood. 2019;134:842.

  251. RIMSZA LM
    PMBL: flying under the immune radar.
    Blood. 2019;134:788-789.

  252. MAURER MJ
    POD24 in MZL: a means to an end or an end point in itself?
    Blood. 2019;134:787-788.

  253. BLUM S, Cairoli A
    Fungal spore contamination mimicking parasitic infection.
    Blood. 2019;134:841.

  254. LUMINARI S, Merli M, Rattotti S, Tarantino V, et al
    Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
    Blood. 2019;134:798-801.
    PubMed     Abstract available

    August 2019
  255. RAUCH DA, Conlon KC, Janakiram M, Brammer JE, et al
    Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade.
    Blood. 2019 Aug 29. pii: blood.2019002038. doi: 10.1182/blood.2019002038.
    PubMed     Abstract available

  256. WANG HY, Hinds BR
    Cutaneous composite small lymphocytic lymphoma and primary cutaneous follicle center lymphoma.
    Blood. 2019;134:717.

  257. LI B, Yan J, Phyu T, Fan S, et al
    MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.
    Blood. 2019 Aug 21. pii: blood.2019000381. doi: 10.1182/blood.2019000381.
    PubMed     Abstract available

  258. HIRAYAMA AV, Gauthier J, Hay KA, Voutsinas JM, et al
    High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
    Blood. 2019;134:636-640.
    PubMed     Abstract available

  259. BISHOP MR
    The case for CAR T-cell therapy in follicular lymphomas.
    Blood. 2019;134:577-578.

  260. CHEN R, Zinzani PL, Lee HJ, Armand P, et al
    Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087.
    Blood. 2019 Aug 13. pii: blood.2019000324. doi: 10.1182/blood.2019000324.
    PubMed     Abstract available

  261. ALMIRE C, Chapuis N
    Too big for flow.
    Blood. 2019;134:576.

  262. FROEHLICH TC, Muller-Decker K, Braun JD, Albrecht T, et al
    Combined inhibition of Bcl-2 and NFkappaB synergistically induces cell death in cutaneous T-cell lymphoma.
    Blood. 2019;134:445-455.
    PubMed     Abstract available

    July 2019
  263. ELFRINK S, de Winde CM, van den Brand M, Berendsen MR, et al
    High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.
    Blood. 2019 Jul 31. pii: blood.2019001185. doi: 10.1182/blood.2019001185.
    PubMed     Abstract available

  264. WANG Y, Link BK, Witzig TE, Maurer MJ, et al
    Impact of Concurrent Indolent Lymphoma on the Clinical Outcome of Newly Diagnosed Diffuse Large B-Cell Lymphoma.
    Blood. 2019 Jul 26. pii: blood.2019000858. doi: 10.1182/blood.2019000858.
    PubMed     Abstract available

  265. STEIDL C
    Targeting GSK3: beyond the mitotic spindle?
    Blood. 2019;134:333-334.

  266. LINDAHL LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, et al
    Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma.
    Blood. 2019 Jul 22. pii: blood.2018888107. doi: 10.1182/blood.2018888107.
    PubMed     Abstract available

  267. STEPHENS DM, Li H, Schoder H, Straus DJ, et al
    Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.
    Blood. 2019 Jul 22. pii: blood.2019000719. doi: 10.1182/blood.2019000719.
    PubMed     Abstract available

  268. FRIGAULT MJ, Dietrich J, Martinez-Lage M, Leick M, et al
    Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma.
    Blood. 2019 Jul 18. pii: blood.2019001694. doi: 10.1182/blood.2019001694.
    PubMed     Abstract available

  269. Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237-245.
    Blood. 2019;134:331.

  270. XU S, Huang Q
    "Double-hit" follicular lymphoma.
    Blood. 2019;134:330.

  271. NAYAK L, Batchelor TT
    Is it time to revisit R-CHOP for primary CNS lymphoma?
    Blood. 2019;134:221-222.

  272. FREEMAN CL, Kridel R, Moccia AA, Savage KJ, et al
    Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma.
    Blood. 2019 Jul 12. pii: blood.2019000258. doi: 10.1182/blood.2019000258.
    PubMed     Abstract available

  273. MOTTOK A, Hung SS, Chavez EA, Woolcock B, et al
    Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.
    Blood. 2019 Jul 10. pii: blood.2019001126. doi: 10.1182/blood.2019001126.
    PubMed     Abstract available

  274. TAN WJ, Wang MM, Ricciardi-Castagnoli P, Tang T, et al
    Single-cell-MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis.
    Blood. 2019 Jul 10. pii: blood.2019000022. doi: 10.1182/blood.2019000022.

  275. KARMALI R, Gordon LI
    Revving up the immune engine in cHL.
    Blood. 2019;134:1-2.

  276. SAUTER CS, Senechal B, Riviere I, Ni A, et al
    CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma.
    Blood. 2019 Jul 1. pii: blood.2018883421. doi: 10.1182/blood.2018883421.
    PubMed     Abstract available

    June 2019
  277. CHAN AC, Vali Betts E
    Mantle cell lymphoma with unusual Burkitt-like morphologic features.
    Blood. 2019;133:2729.

  278. KWON R, Duffield AS
    HTLV-1-associated adult T-cell leukemia/lymphoma with disseminated strongyloidiasis.
    Blood. 2019;133:2623.

  279. SPERLING S, Fiedler P, Lechner M, Pollithy A, et al
    Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.
    Blood. 2019;133:2597-2609.
    PubMed     Abstract available

  280. MURRAY PG, Young LS
    An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma.
    Blood. 2019 Jun 11. pii: blood.2019000568. doi: 10.1182/blood.2019000568.
    PubMed     Abstract available

  281. ABRAMSON JS, Arnason JE, LaCasce AS, Redd R, et al
    Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma.
    Blood. 2019 Jun 11. pii: blood.2019001272. doi: 10.1182/blood.2019001272.
    PubMed     Abstract available

    May 2019
  282. ZHANG JP, Song Z, Wang HB, Lang L, et al
    A novel model of controlling PD-L1 expression in ALK+ Anaplastic Large Cell Lymphoma revealed by CRISPR screening.
    Blood. 2019 May 31. pii: blood.2019001043. doi: 10.1182/blood.2019001043.
    PubMed     Abstract available

  283. SUBTIL A, Xu Z
    Follicular lymphoma with composite in situ mantle cell neoplasia.
    Blood. 2019;133:2460.

  284. PASCUAL M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, et al
    PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
    Blood. 2019;133:2401-2412.
    PubMed     Abstract available

  285. MARTINO G, Ascani S
    Seronegative visceral leishmaniasis with bone marrow and hepatic involvement.
    Blood. 2019;133:2353.

  286. RUMI E, Zibellini S
    JAK inhibitors and risk of B-cell lymphomas.
    Blood. 2019;133:2251-2253.

  287. FERRERI AJM, Calimeri T, Conte GM, Cattaneo D, et al
    R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-alpha in primary CNS lymphoma.
    Blood. 2019 May 22. pii: blood.2019000633. doi: 10.1182/blood.2019000633.
    PubMed     Abstract available

  288. ZUCCA E, Rondeau S, Vanazzi A, Ostenstad B, et al
    Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
    Blood. 2019 May 17. pii: blood-2018-10-879643. doi: 10.1182/blood-2018-10-879643
    PubMed     Abstract available

  289. STRATI P, Nastoupil LJ, Fayad LE, Samaniego F, et al
    Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection.
    Blood. 2019 May 17. pii: blood.2019000888. doi: 10.1182/blood.2019000888.

  290. LUCHTEL RA, Zimmermann MT, Hu G, Dasari S, et al
    Recurrent MSC (E116K) mutations in ALK-negative anaplastic large cell lymphoma.
    Blood. 2019 May 17. pii: blood.2019000626. doi: 10.1182/blood.2019000626.
    PubMed     Abstract available

  291. WU X, Stenson M, Abeykoon J, Nowakowski KE, et al
    Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
    Blood. 2019 May 17. pii: blood.2018874560. doi: 10.1182/blood.2018874560.
    PubMed     Abstract available

    To treat or not to treat, that is the NLPHL question.
    Blood. 2019;133:2113-2114.

  293. KARSCHNIA P, Jordan JT, Forst DA, Arrillaga-Romany IC, et al
    Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
    Blood. 2019;133:2212-2221.
    PubMed     Abstract available

  294. PANAITE L, Shadman M
    Concurrent diagnosis of classical Hodgkin lymphoma and Langerhans cell histiocytosis.
    Blood. 2019;133:2109.

  295. HERBAUX C, Davids MS
    Venetoclax: R-CHOP rocket booster?
    Blood. 2019;133:1922-1924.

    April 2019
  296. BALAKRISHNA JP, Jones D
    A young woman with intravascular large B-cell lymphoma in a benign-appearing endometrial polyp.
    Blood. 2019;133:1920.

    CAR-T efficacy: is conditioning the key?
    Blood. 2019;133:1799-1800.

  298. FORERO-TORRES A, Ramchandren R, Yacoub A, Wertheim MS, et al
    Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies.
    Blood. 2019;133:1742-1752.
    PubMed     Abstract available

  299. WILLEMZE R, Cerroni L, Kempf W, Berti E, et al
    The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.
    Blood. 2019;133:1703-1714.
    PubMed     Abstract available

  300. NOY A
    Optimizing treatment for HIV-associated lymphoma.
    Blood. 2019 Apr 16. pii: blood-2018-01-791400. doi: 10.1182/blood-2018-01-791400
    PubMed     Abstract available

  301. ZHAN Y, Teruya-Feldstein J
    Immune dysregulation: EBV(+) DLBCL and HLH in a patient with T-LGL.
    Blood. 2019;133:1695.

  302. WITZIG TE, Inwards D
    Acalabrutinib for Mantle Cell Lymphoma.
    Blood. 2019 Apr 9. pii: blood.2019852368. doi: 10.1182/blood.2019852368.
    PubMed     Abstract available

  303. ARMAND P, Chen YB, Redd RA, Joyce RM, et al
    PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.
    Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215.
    PubMed     Abstract available

    March 2019
  304. SONG JY, Herrera AF
    CAR T cells mimicking an aggressive lymphoma.
    Blood. 2019;133:1517.

  305. GODFREY J, Tumuluru S, Bao R, Leukam M, et al
    PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype.
    Blood. 2019 Mar 25. pii: blood-2018-10-879015. doi: 10.1182/blood-2018-10-879015
    PubMed     Abstract available

  306. Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132(16):1635-1646.
    Blood. 2019;133:1384-1385.

  307. STREFFORD JC, Oscier DG
    A unique genome in EBV-positive BL.
    Blood. 2019;133:1269-1270.

  308. ZELENETZ AD, Salles G, Mason KD, Casulo C, et al
    Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
    Blood. 2019 Mar 8. pii: blood-2018-11-880526. doi: 10.1182/blood-2018-11-880526.
    PubMed     Abstract available

  309. ALLAN JM
    Genetic susceptibility to breast cancer in lymphoma survivors.
    Blood. 2019;133:1004-1006.

    February 2019
  310. CAIRO MS
    A new Burkitt "look-alike" lymphoma.
    Blood. 2019;133:889-891.

  311. FOX CP
    Refining CNS relapse risk in DLBCL: easy as ABC?
    Blood. 2019;133:886-888.

  312. KLANOVA M, Sehn LH, Bence-Bruckler I, Cavallo F, et al
    Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
    Blood. 2019;133:919-926.
    PubMed     Abstract available

  313. DOBROVOLSKY D, Wang ES, Morrow S, Leahy C, et al
    Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
    Blood. 2019;133:952-961.
    PubMed     Abstract available

  314. PEMMARAJU N, Kantarjian H, Nastoupil L, Dupuis M, et al
    Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
    Blood. 2019 Feb 22. pii: blood-2019-01-897637. doi: 10.1182/blood-2019-01-897637

  315. GARCES S, Sriganeshan V
    Fibrin-associated diffuse large B-cell lymphoma confined to a cardiac myxoma.
    Blood. 2019;133:882.

  316. KHODADOUST MS, Olsson N, Chen B, Sworder B, et al
    B-cell lymphomas present immunoglobulin neoantigens.
    Blood. 2019;133:878-881.

  317. HIRAYAMA AV, Gauthier J, Hay KA, Voutsinas JM, et al
    The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells.
    Blood. 2019 Feb 19. pii: blood-2018-11-887067. doi: 10.1182/blood-2018-11-887067
    PubMed     Abstract available

  318. LURAIN K, Polizzotto MN, Aleman K, Bhutani M, et al
    Viral, immunologic, and clinical features of primary effusion lymphoma.
    Blood. 2019 Feb 19. pii: blood-2019-01-893339. doi: 10.1182/blood-2019-01-893339
    PubMed     Abstract available

  319. HEAVICAN TB, Bouska A, Yu J, Lone W, et al
    Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
    Blood. 2019 Feb 19. pii: blood-2018-09-872549. doi: 10.1182/blood-2018-09-872549
    PubMed     Abstract available

  320. BORCHMANN S, Joffe E, Moskowitz CH, Zelenetz AD, et al
    Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
    Blood. 2019 Feb 15. pii: blood-2018-10-877761. doi: 10.1182/blood-2018-10-877761
    PubMed     Abstract available

  321. SU RJ, Said J
    Intraocular toxoplasmosis mimicking vitreous lymphoma.
    Blood. 2019;133:767.

  322. Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670-2681.
    Blood. 2019;133:620.

    Functional profiling to improve therapy in TCL.
    Blood. 2019;133:504-506.

  324. KOCH R, Christie AL, Crombie JL, Palmer AC, et al
    Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.
    Blood. 2019;133:566-575.
    PubMed     Abstract available

  325. HSI ED, Li H, Nixon AB, Schoder H, et al
    Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
    Blood. 2019 Feb 5. pii: blood-2018-08-870915. doi: 10.1182/blood-2018-08-870915.
    PubMed     Abstract available

    January 2019
    Unusual presentation of classic Hodgkin lymphoma.
    Blood. 2019;133:502.

  327. CASULO C, Barr PM
    How I treat early relapsing follicular lymphoma.
    Blood. 2019 Jan 30. pii: blood-2018-08-822148. doi: 10.1182/blood-2018-08-822148
    PubMed     Abstract available

  328. VON HOFF L, Kargel E, Franke V, McShane E, et al
    Autocrine LTA signaling drives NF-kappaB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
    Blood. 2019 Jan 29. pii: blood-2018-08-871293. doi: 10.1182/blood-2018-08-871293
    PubMed     Abstract available

  329. MARTIN P, Bartlett NL, Blum KA, Park S, et al
    A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood. 2019 Jan 28. pii: blood-2018-11-886457. doi: 10.1182/blood-2018-11-886457
    PubMed     Abstract available

  330. MOSHREF RAZAVI H, Hrynchak M
    Unusual presentation of Burkitt-like lymphoma with 11q aberration in an elderly patient.
    Blood. 2019;133:381.

  331. MONTOTO S
    Localized FL: how long in response to be cured?
    Blood. 2019;133:187-188.

  332. MATSUE K, Abe Y, Kitadate A, Miura D, et al
    Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma.
    Blood. 2019 Jan 15. pii: blood-2018-11-887570. doi: 10.1182/blood-2018-11-887570

  333. HICKS LK, Feld JJ
    Resolved HBV and anti-CD20 therapy.
    Blood. 2019;133:104-106.

  334. AUSSEDAT G, Baseggio L
    One translocation for 2 lymphoid neoplasms.
    Blood. 2019;133:180.

  335. GRANDE BM, Gerhard DS, Jiang A, Griner NB, et al
    Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma.
    Blood. 2019 Jan 7. pii: blood-2018-09-871418. doi: 10.1182/blood-2018-09-871418.
    PubMed     Abstract available

  336. BOJARCZUK K, Wienand K, Ryan JA, Chen L, et al
    Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Blood. 2019;133:70-80.
    PubMed     Abstract available

    December 2018
  337. ANDOR N, Simonds EF, Czerwinski DK, Chen J, et al
    Single-cell RNA-Seq of lymphoma cancers reveals malignant B cell types and co-expression of T cell immune checkpoints.
    Blood. 2018 Dec 27. pii: blood-2018-08-862292. doi: 10.1182/blood-2018-08-862292
    PubMed     Abstract available

  338. OPSTAL-VAN WINDEN AWJ, de Haan HG, Hauptmann M, Schmidt MK, et al
    Genetic susceptibility to radiation-induced breast cancer after Hodgkin Lymphoma.
    Blood. 2018 Dec 20. pii: blood-2018-07-862607. doi: 10.1182/blood-2018-07-862607
    PubMed     Abstract available

  339. GROMMES C, Tang SS, Wolfe J, Kaley TJ, et al
    Phase Ib trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Blood. 2018 Dec 19. pii: blood-2018-09-875732. doi: 10.1182/blood-2018-09-875732
    PubMed     Abstract available

  340. WAGENER R, Seufert J, Raimondi F, Bens S, et al
    The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
    Blood. 2018 Dec 19. pii: blood-2018-07-864025. doi: 10.1182/blood-2018-07-864025
    PubMed     Abstract available

  341. JANZ S
    New wrinkle on deubiquitination in B-cell lymphoma.
    Blood. 2018;132:2529-2530.

  342. MARTIN-GARCIA D, Navarro A, Valdes-Mas R, Clot G, et al
    CCND2 and CCND3 hijack immunoglobulin light chain enhancers in cyclin D1-negative mantle cell lymphoma.
    Blood. 2018 Dec 11. pii: blood-2018-07-862151. doi: 10.1182/blood-2018-07-862151
    PubMed     Abstract available

  343. MOHANTY A, Sandoval N, Phan A, Nguyen TV, et al
    Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
    Blood. 2018 Dec 10. pii: blood-2018-05-851667. doi: 10.1182/blood-2018-05-851667
    PubMed     Abstract available

  344. PICARDI M, Della Pepa R, Giordano C, Zacheo I, et al
    Tenofovir versus lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.
    Blood. 2018 Dec 7. pii: blood-2018-10-878892. doi: 10.1182/blood-2018-10-878892.

  345. MENDEVILLE M, Roemer MGM, van den Hout MFCM, Los-de Vries GT, et al
    Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.
    Blood. 2018 Dec 3. pii: blood-2017-12-822171. doi: 10.1182/blood-2017-12-822171.

    November 2018
    A small change makes a big difference in Hodgkin lymphoma.
    Blood. 2018;132:2214-2215.

  347. QU X, Li H, Braziel RM, Passerini V, et al
    Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016.
    Blood. 2018 Nov 16. pii: blood-2018-07-865428. doi: 10.1182/blood-2018-07-865428
    PubMed     Abstract available

  348. BRADY JL, Binkley MS, Hajj C, Chelius M, et al
    Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG.
    Blood. 2018 Nov 16. pii: blood-2018-04-843540. doi: 10.1182/blood-2018-04-843540
    PubMed     Abstract available

  349. DREYLING M, Klapper W, Rule S
    Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
    Blood. 2018 Nov 1. pii: blood-2017-08-737502. doi: 10.1182/blood-2017-08-737502.
    PubMed     Abstract available

    October 2018
  350. GRALEWSKI J, Post GR
    Cutaneous intralymphatic CD30(+) pseudolymphoma: a reactive condition mimicking lymphoma.
    Blood. 2018;132:1859.

  351. KUSUMOTO S, Arcaini L, Hong X, Jin J, et al
    Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Blood. 2018 Oct 19. pii: blood-2018-04-848044. doi: 10.1182/blood-2018-04-848044
    PubMed     Abstract available

  352. KANAAN C, Burroni B
    Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma.
    Blood. 2018;132:1725.

  353. DANIEL R, Chan RY
    Hyperviscosity syndrome in splenic marginal zone lymphoma.
    Blood. 2018;132:1627.

    Next-generation therapy for follicular lymphoma.
    Blood. 2018;132:1465-1467.

  355. LEMONNIER F, Dupuis J, Sujobert P, Tournillhac O, et al
    Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.
    Blood. 2018 Oct 2. pii: blood-2018-04-840538. doi: 10.1182/blood-2018-04-840538.

    September 2018
  356. MOSKOWITZ CH, Walewski J, Nademanee A, Masszi T, et al
    Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
    Blood. 2018 Sep 28. pii: blood-2018-07-861641. doi: 10.1182/blood-2018-07-861641
    PubMed     Abstract available

  357. TUN HW, Johnston PB, DeAngelis LM, Atherton PJ, et al
    Phase I study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreo-retinal lymphoma.
    Blood. 2018 Sep 27. pii: blood-2018-02-835496. doi: 10.1182/blood-2018-02-835496
    PubMed     Abstract available

  358. MCLAUGHLIN LP, Rouce R, Gottschalk S, Torrano V, et al
    EBV/LMP-specific T cells maintain remissions of T and B cell EBV lymphomas after allogeneic bone marrow transplantation.
    Blood. 2018 Sep 27. pii: blood-2018-07-863654. doi: 10.1182/blood-2018-07-863654
    PubMed     Abstract available

  359. MOTTOK A, Wright G, Rosenwald A, Ott G, et al
    Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.
    Blood. 2018 Sep 26. pii: blood-2018-05-851154. doi: 10.1182/blood-2018-05-851154
    PubMed     Abstract available

  360. ELSHIEKH M, Naresh KN
    A rare case of renal intravascular NK/T-cell lymphoma.
    Blood. 2018;132:1354.

  361. MUSILOVA K, Devan J, Cerna K, Seda V, et al
    miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
    Blood. 2018 Sep 13. pii: blood-2018-06-855502. doi: 10.1182/blood-2018-06-855502
    PubMed     Abstract available

  362. LI L, Zhang J, Chen J, Xu-Monette ZY, et al
    B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
    Blood. 2018 Sep 12. pii: blood-2018-03-841015. doi: 10.1182/blood-2018-03-841015
    PubMed     Abstract available

  363. MEHTA-SHAH N, Clemens MW, Horwitz SM
    How I treat breast implant-associated anaplastic large cell lymphoma.
    Blood. 2018 Sep 12. pii: blood-2018-03-785972. doi: 10.1182/blood-2018-03-785972
    PubMed     Abstract available

  364. KAMIJO H, Miyagaki T, Shishido-Takahashi N, Nakajima R, et al
    Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Blood. 2018 Sep 7. pii: blood-2018-04-845834. doi: 10.1182/blood-2018-04-845834.
    PubMed     Abstract available

  365. SUD A, Thomsen H, Orlando G, Forsti A, et al
    Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.
    Blood. 2018 Sep 7. pii: blood-2018-06-855296. doi: 10.1182/blood-2018-06-855296.
    PubMed     Abstract available

  366. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.

    CART19 in Hodgkin lymphoma: are we driving the right model?
    Blood. 2018;132:982-983.

  368. RUAN J, Martin P, Christos P, Cerchietti L, et al
    Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
    Blood. 2018 Sep 4. pii: blood-2018-07-859769. doi: 10.1182/blood-2018-07-859769.
    PubMed     Abstract available

    August 2018
  369. KOBE C, Goergen H, Baues C, Kuhnert G, et al
    Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
    Blood. 2018 Aug 30. pii: blood-2018-05-852129. doi: 10.1182/blood-2018-05-852129
    PubMed     Abstract available

    Update on Mantle Cell Lymphoma.
    Blood. 2018 Aug 28. pii: blood-2018-03-791392. doi: 10.1182/blood-2018-03-791392
    PubMed     Abstract available

  371. SHIMADA K, Hayakawa F, Kiyoi H
    Biology and management of primary effusion lymphoma.
    Blood. 2018 Aug 28. pii: blood-2018-03-791426. doi: 10.1182/blood-2018-03-791426
    PubMed     Abstract available

    The run-down immunologic neighborhood in Hodgkin lymphoma.
    Blood. 2018;132:770-771.

  373. HELLMUTH JC, Louissaint A Jr, Szczepanowski M, Haebe S, et al
    Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles.
    Blood. 2018 Aug 20. pii: blood-2018-03-837252. doi: 10.1182/blood-2018-03-837252
    PubMed     Abstract available

  374. PONZONI M, Campo E, Nakamura S
    Blood. 2018 Aug 15. pii: blood-2017-04-737445. doi: 10.1182/blood-2017-04-737445
    PubMed     Abstract available

  375. DABAJA BS, Hoppe BS, Plastaras JP, Newhauser W, et al
    Blood. 2018 Aug 14. pii: blood-2018-03-837633. doi: 10.1182/blood-2018-03-837633
    PubMed     Abstract available

  376. LU X, Fernando T, Lossos C, Yusufova N, et al
    PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
    Blood. 2018 Aug 6. pii: blood-2018-02-831438. doi: 10.1182/blood-2018-02-831438.
    PubMed     Abstract available

  377. MORSCHHAUSER F, Salles G, Le Gouill S, Tilly H, et al
    An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
    PubMed     Abstract available

    July 2018
  378. EICHENAUER DA, Plutschow A, Schroder L, Fuchs M, et al
    Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Blood. 2018 Jul 31. pii: blood-2018-02-836437. doi: 10.1182/blood-2018-02-836437
    PubMed     Abstract available

  379. MARKS LJ, McCarten K, Pei Q, Friedman DL, et al
    Pericardial Effusion in Hodgkin Lymphoma: A Report from the Children's Oncology Group AHOD0031.
    Blood. 2018 Jul 30. pii: blood-2018-02-834465. doi: 10.1182/blood-2018-02-834465

  380. SONG TL, Nairismagi ML, Laurensia Y, Lim JQ, et al
    Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma.
    Blood. 2018 Jul 27. pii: blood-2018-01-829424. doi: 10.1182/blood-2018-01-829424
    PubMed     Abstract available

  381. STRAUS DJ, Jung SH, Pitcher B, Kostakoglu L, et al
    CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Blood. 2018 Jul 26. pii: blood-2018-01-827246. doi: 10.1182/blood-2018-01-827246
    PubMed     Abstract available

  382. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.
    Blood. 2018;132:458-459.

  383. GOLDSTEIN JS, Nastoupil LJ, Han X, Jemal A, et al
    Disparities in survival by insurance status in follicular lymphoma.
    Blood. 2018 Jul 24. pii: blood-2018-03-839035. doi: 10.1182/blood-2018-03-839035
    PubMed     Abstract available

  384. HOSER D, Schon C, Loddenkemper C, Lohneis P, et al
    Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice.
    Blood. 2018 Jul 12. pii: blood-2018-02-834036. doi: 10.1182/blood-2018-02-834036
    PubMed     Abstract available

  385. ILLERHAUS G, Schorb E, Kasenda B
    Novel agents for primary central nervous system lymphoma (PCNSL): evidence and perspectives.
    Blood. 2018 Jul 9. pii: blood-2018-01-791558. doi: 10.1182/blood-2018-01-791558.
    PubMed     Abstract available

  386. GORDON LI
    Getting to transplant in Hodgkin lymphoma: BVB.
    Blood. 2018;132:1-3.

    How I treat primary mediastinal B-cell lymphoma.
    Blood. 2018 Jul 5. pii: blood-2018-04-791566. doi: 10.1182/blood-2018-04-791566.
    PubMed     Abstract available

    June 2018
  388. ALRABEH R, Hao S
    "Double-expressor" intravascular large B-cell lymphoma involving the female genital tract.
    Blood. 2018;131:2993.

  389. PATIL A, Manzano M, Gottwein E
    CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Blood. 2018 Jun 28. pii: blood-2018-01-828418. doi: 10.1182/blood-2018-01-828418
    PubMed     Abstract available

  390. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991

  391. SVOBODA J, Rheingold SR, Gill SI, Grupp SA, et al
    Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma.
    Blood. 2018 Jun 20. pii: blood-2018-03-837609. doi: 10.1182/blood-2018-03-837609
    PubMed     Abstract available

  392. OISHI N, Brody GS, Ketterling RP, Viswanatha DS, et al
    Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.
    Blood. 2018 Jun 19. pii: blood-2017-12-821868. doi: 10.1182/blood-2017-12-821868

  393. KALPADAKIS C, Pangalis GA, Sachanas S, Tsirkinidis P, et al
    Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
    Blood. 2018 Jun 18. pii: blood-2018-02-833608. doi: 10.1182/blood-2018-02-833608

  394. CHOW VA, Shadman M, Gopal AK
    Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma.
    Blood. 2018 Jun 18. pii: blood-2018-04-839217. doi: 10.1182/blood-2018-04-839217
    PubMed     Abstract available

  395. FLERLAGE JE, Metzger ML, Bhakta N
    The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?
    Blood. 2018 Jun 12. pii: blood-2018-01-778548. doi: 10.1182/blood-2018-01-778548
    PubMed     Abstract available

  396. CADER FZ, Schackmann RCJ, Hu X, Wienand K, et al
    Mass cytometry of Hodgkin lymphoma reveals a CD4(+) exhausted T-effector and T-regulatory cell rich microenvironment.
    Blood. 2018 Jun 7. pii: blood-2018-04-843714. doi: 10.1182/blood-2018-04-843714.
    PubMed     Abstract available

  397. BOUDESCO C, Verhoeyen E, Martin L, Chassagne-Clement C, et al
    HSP110 sustains chronic NF-kappaB signaling in activated B cell diffuse large B cell lymphoma through MyD88 stabilization.
    Blood. 2018 Jun 5. pii: blood-2017-12-819706. doi: 10.1182/blood-2017-12-819706.
    PubMed     Abstract available

  398. ADAMS HJA, Kwee TC
    Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven.
    Blood. 2018 Jun 1. pii: blood-2018-04-845438. doi: 10.1182/blood-2018-04-845438.

    May 2018
  399. NAKAYAMA S, Matsuda M
    25-Hydroxyvitamin D3-1alpha-hydroxylase- and multiple cytokine-producing diffuse large B-cell lymphoma.
    Blood. 2018;131:2271.

  400. GOPAL S, Gross TG
    How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.
    Blood. 2018 May 16. pii: blood-2018-04-844472. doi: 10.1182/blood-2018-04-844472
    PubMed     Abstract available

  401. CLOT G, Jares P, Gine E, Navarro A, et al
    A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.
    Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136
    PubMed     Abstract available

  402. MANSON G, Herbaux C, Brice P, Bouabdallah K, et al
    Prolonged remissions after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
    Blood. 2018 May 3. pii: blood-2018-03-841262. doi: 10.1182/blood-2018-03-841262.

  403. HU S, Wang Y
    Diffuse large B-cell lymphoma with strong aberrant expression of CD31.
    Blood. 2018;131:2090.

  404. HERBAUX C, Merryman R, Devine S, Armand P, et al
    Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
    Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
    PubMed     Abstract available

  405. CERIANI L, Milan L, Martelli M, Ferreri AJM, et al
    Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
    Blood. 2018 May 2. pii: blood-2018-01-826958. doi: 10.1182/blood-2018-01-826958.
    PubMed     Abstract available

    April 2018
  406. LACASCE AS, Bociek RG, Sawas A, Caimi P, et al
    Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    Blood. 2018 Apr 27. pii: blood-2017-11-815183. doi: 10.1182/blood-2017-11-815183
    PubMed     Abstract available

  407. SCHMITZ N, Lenz G, Stelljes M
    Allogeneic hematopoietic stem cell transplantation (HSCT) for T-cell lymphomas.
    Blood. 2018 Apr 26. pii: blood-2018-01-791335. doi: 10.1182/blood-2018-01-791335
    PubMed     Abstract available

  408. PHILLIPS TJ, Forero-Torres A, Sher T, Diefenbach CS, et al
    Phase 1 study of the PI3Kdelta inhibitor INCB040093 +/- JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
    Blood. 2018 Apr 25. pii: blood-2017-10-812701. doi: 10.1182/blood-2017-10-812701
    PubMed     Abstract available

  409. HIGUCHI H, Yamakawa N, Imadome KI, Yahata T, et al
    Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma.
    Blood. 2018 Apr 22. pii: blood-2017-07-794529. doi: 10.1182/blood-2017-07-794529
    PubMed     Abstract available

  410. CHUNG BM, Zieske AW
    Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index.
    Blood. 2018;131:1874.

  411. BACHY E, Maurer MJ, Habermann TM, Gelas-Dore B, et al
    A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
    Blood. 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405
    PubMed     Abstract available

  412. KUPPERS R, Stevenson FK
    Critical influences on the pathogenesis of follicular lymphoma.
    Blood. 2018 Apr 17. pii: blood-2017-11-764365. doi: 10.1182/blood-2017-11-764365
    PubMed     Abstract available

  413. PASQUALUCCI L, Dalla-Favera R
    Genetics of diffuse large B cell lymphoma.
    Blood. 2018 Apr 17. pii: blood-2017-11-764332. doi: 10.1182/blood-2017-11-764332
    PubMed     Abstract available

  414. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Abstract available

  415. JETHWA A, Slabicki M, Hullein J, Jentzsch M, et al
    TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Blood. 2018 Apr 13. pii: blood-2017-09-806679. doi: 10.1182/blood-2017-09-806679
    PubMed     Abstract available

  416. TIACCI E, Ladewig E, Schiavoni G, Penson A, et al
    Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
    Blood. 2018 Apr 12. pii: blood-2017-11-814913. doi: 10.1182/blood-2017-11-814913
    PubMed     Abstract available

  417. KUBOTA Y, Kusaba K
    Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system.
    Blood. 2018;131:1765.

  418. JIANG X, Zhou D
    ALK(+) small cell variant of anaplastic large cell lymphoma with leukemic presentation.
    Blood. 2018;131:1764.

    Lymphoma exosomes reprogram the bone marrow.
    Blood. 2018;131:1635-1636.

  420. STELLING A, Hashwah H, Bertram K, Manz MG, et al
    The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.
    Blood. 2018 Apr 3. pii: blood-2017-10-810630. doi: 10.1182/blood-2017-10-810630.
    PubMed     Abstract available

    March 2018
  421. YAMAGUCHI M, Suzuki R, Oguchi M
    Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Blood. 2018 Mar 30. pii: blood-2017-12-791418. doi: 10.1182/blood-2017-12-791418
    PubMed     Abstract available

  422. BATTISTELLO E, Katanayeva N, Dheilly E, Tavernari D, et al
    Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
    Blood. 2018 Mar 22. pii: blood-2017-10-809210. doi: 10.1182/blood-2017-10-809210
    PubMed     Abstract available

  423. COTTEREAU AS, Versari A, Luminari S, Dupuis J, et al
    Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
    Blood. 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
    PubMed     Abstract available

  424. WANG HY, Jaffe ES
    An anaplastic T-cell lymphoma mimicking classical Hodgkin lymphoma.
    Blood. 2018;131:1262.

  425. BRICE P
    Refractory Hodgkin lymphoma: time for targeted therapies?
    Blood. 2018;131:1156-1157.

  426. REN W, Ye X, Su H, Li W, et al
    Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.
    Blood. 2018 Mar 15. pii: blood-2017-11-817601. doi: 10.1182/blood-2017-11-817601
    PubMed     Abstract available

  427. SMITH M, Zakrzewski J, James S, Sadelain M, et al
    Posttransplant chimeric antigen receptor therapy.
    Blood. 2018;131:1045-1052.
    PubMed     Abstract available

  428. ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
    ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Blood. 2018;131:1094-1105.
    PubMed     Abstract available

  429. SCHRADER AMR, Jansen PM, Willemze R, Vermeer MH, et al
    High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
    Blood. 2018 Mar 7. pii: blood-2017-12-822817. doi: 10.1182/blood-2017-12-822817.

  430. MOTTOK A, Steidl C
    Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.
    Blood. 2018 Mar 2. pii: blood-2017-09-772632. doi: 10.1182/blood-2017-09-772632.
    PubMed     Abstract available

  431. BROCKELMANN PJ, Sasse S, Engert A
    Early-stage classical Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-10-772665. doi: 10.1182/blood-2017-10-772665.
    PubMed     Abstract available

  432. LIM SH, Johnson PWM
    Optimizing therapy in advanced stage Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-09-772640. doi: 10.1182/blood-2017-09-772640.
    PubMed     Abstract available

  433. SEHN LH
    Introduction to a review series on Hodgkin Lymphoma: Change is here.
    Blood. 2018 Mar 2. pii: blood-2018-02-824045. doi: 10.1182/blood-2018-02-824045.

  434. MEHTA-SHAH N, Bartlett NL
    Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
    Blood. 2018 Mar 2. pii: blood-2017-09-772681. doi: 10.1182/blood-2017-09-772681.
    PubMed     Abstract available

  435. SHAH GL, Moskowitz CH
    Transplant strategies in relapsed/refractory Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-09-772673. doi: 10.1182/blood-2017-09-772673.
    PubMed     Abstract available

  436. Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017;130(20):2180-2185.
    Blood. 2018;131:1037.

    February 2018
  437. SCOTT DW, King RL, Staiger AM, Ben-Neriah S, et al
    High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
    Blood. 2018 Feb 23. pii: blood-2017-12-820605. doi: 10.1182/blood-2017-12-820605
    PubMed     Abstract available

  438. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.

  439. BRAUE JA, Daniels AB, Zwerner JP, Kim SJ, et al
    Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4(+) to CD8<sup/>.
    Blood. 2018;131:932-935.

  440. VIGANO E, Gunawardana J, Mottok A, Van Tol T, et al
    Somatic IL4R Mutations in Primary Mediastinal Large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.
    Blood. 2018 Feb 21. pii: blood-2017-09-808907. doi: 10.1182/blood-2017-09-808907
    PubMed     Abstract available

  441. VARI F, Arpon D, Keane C, Hertzberg MS, et al
    Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
    Blood. 2018 Feb 15. pii: blood-2017-07-796342. doi: 10.1182/blood-2017-07-796342
    PubMed     Abstract available

  442. SPINA V, Bruscaggin A, Cuccaro A, Martini M, et al
    Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma.
    Blood. 2018 Feb 15. pii: blood-2017-11-812073. doi: 10.1182/blood-2017-11-812073
    PubMed     Abstract available

  443. ZHAO X, Tao J
    BRD4: epigenetic origin and target of CTCL.
    Blood. 2018;131:712-713.

  444. WASIK MA
    Distinct miRNA profile in prognosis of early CTCL.
    Blood. 2018;131:711.

  445. LINDAHL LM, Besenbacher S, Rittig AH, Celis P, et al
    Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study.
    Blood. 2018;131:759-770.
    PubMed     Abstract available

  446. GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
    CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
    Blood. 2018;131:611-620.
    PubMed     Abstract available

  447. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
    Blood. 2018;131:587-588.

  448. COTTEREAU AS, Versari A, Loft A, Casasnovas O, et al
    Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial.
    Blood. 2018 Feb 1. pii: blood-2017-07-795476. doi: 10.1182/blood-2017-07-795476.
    PubMed     Abstract available

  449. JIANG W, Zhou X, Li Z, Liu K, et al
    Prolyl 4-Hydroxylase 2 Promotes B-cell Lymphoma Progression via Hydroxylation of Carabin.
    Blood. 2018 Feb 1. pii: blood-2017-07-794875. doi: 10.1182/blood-2017-07-794875.
    PubMed     Abstract available

    January 2018
  450. VOSE JM
    Peripheral T-cell lymphoma: novel backbone.
    Blood. 2018;131:375-376.

  451. ZIJLSTRA JM, Boellaard R
    Baseline PET as prognostic marker for Hodgkin?
    Blood. 2018;131:3-4.

  452. XU-MONETTE ZY, Zhou J, Young KH
    PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Blood. 2018;131:68-83.
    PubMed     Abstract available

  453. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Abstract available

    December 2017
  454. BATTISTELLA M, Leboeuf C, Ram-Wolff C, Hurabielle C, et al
    KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Blood. 2017;130:2900-2902.

  455. FRIEDBERG JW, Forero-Torres A, Bordoni RE, Cline VJM, et al
    Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL.
    Blood. 2017;130:2829-2837.
    PubMed     Abstract available

    ALCL: is it now a curable disease?
    Blood. 2017;130:2691-2692.

  457. HORWITZ SM, Koch R, Porcu P, Oki Y, et al
    Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.
    Blood. 2017 Dec 12. pii: blood-2017-08-802470. doi: 10.1182/blood-2017-08-802470
    PubMed     Abstract available

  458. HERRERA AF, Moskowitz AJ, Bartlett NL, Vose JM, et al
    Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2017 Dec 11. pii: blood-2017-10-811224. doi: 10.1182/blood-2017-10-811224
    PubMed     Abstract available

    November 2017
  459. STEIDL C
    The ecosystem of classical Hodgkin lymphoma.
    Blood. 2017;130:2360-2361.

  460. KOHNKEN R, Wen J, Mundy-Bosse B, McConnell K, et al
    Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Blood. 2017 Nov 27. pii: blood-2017-09-805663. doi: 10.1182/blood-2017-09-805663
    PubMed     Abstract available

  461. LIU WR, Shipp MA
    Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Blood. 2017;130:2265-2270.
    PubMed     Abstract available

  462. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.

  463. GREEN MR
    Chromatin modifying gene mutations in follicular lymphoma.
    Blood. 2017 Nov 20. pii: blood-2017-08-737361. doi: 10.1182/blood-2017-08-737361
    PubMed     Abstract available

  464. Diffuse large B-cell lymphoma in the elderly.
    Blood. 2017;130:2235.

  465. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.

    Relapsed/refractory HL: FDG-PET is the trump card.
    Blood. 2017;130:2154-2155.

  467. AMENGUAL JE, Lichtenstein R, Lue J, Sawas A, et al
    A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Blood. 2017 Nov 15. pii: blood-2017-09-806737. doi: 10.1182/blood-2017-09-806737
    PubMed     Abstract available

  468. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.

  469. MOTTOK A, Jurinovic V, Farinha P, Rosenwald A, et al
    FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens.
    Blood. 2017 Nov 9. pii: blood-2017-08-799080. doi: 10.1182/blood-2017-08-799080.
    PubMed     Abstract available

  470. RYAN MC, Palanca-Wessels MC, Schimpf B, Gordon KA, et al
    Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
    Blood. 2017;130:2018-2026.
    PubMed     Abstract available

    October 2017
  471. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Abstract available

  472. FISH K, Sora RP, Schaller SJ, Longnecker R, et al
    EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Blood. 2017 Oct 26. pii: blood-2017-07-796821. doi: 10.1182/blood-2017-07-796821
    PubMed     Abstract available

  473. BARTLETT NL, Costello BA, LaPlant BR, Ansell SM, et al
    Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial.
    Blood. 2017 Oct 26. pii: blood-2017-09-804641. doi: 10.1182/blood-2017-09-804641
    PubMed     Abstract available

  474. LAMY T, Damaj G, Soubeyran P, Gyan E, et al
    R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL).
    Blood. 2017 Oct 23. pii: blood-2017-07-793984. doi: 10.1182/blood-2017-07-793984
    PubMed     Abstract available

  475. Genomic analysis of adult Burkitt lymphoma.
    Blood. 2017;130:1871.

  476. PILERI SA
    Understanding lymphoma molecular complexity.
    Blood. 2017;130:1780-1781.

  477. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.

  478. AKHTARI M, Milgrom SA, Pinnix CC, Reddy JP, et al
    Re-classifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
    Blood. 2017 Oct 16. pii: blood-2017-04-773838. doi: 10.1182/blood-2017-04-773838
    PubMed     Abstract available

    Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma.
    Blood. 2017;130:1683.

  480. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Abstract available

  481. PRO B, Advani R, Brice P, Bartlett NL, et al
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
    Blood. 2017 Oct 3. pii: blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049.
    PubMed     Abstract available

  482. CYRENNE BM, Lewis J, Weed J, Carlson K, et al
    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood. 2017 Oct 2. pii: blood-2017-06-792150. doi: 10.1182/blood-2017-06-792150.
    PubMed     Abstract available

    September 2017

  483. MALT lymphoma prognostic index.
    Blood. 2017;130:1486.

  484. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.

  485. PARK J, Yang J, Wenzel AT, Ramachandran A, et al
    Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
    Blood. 2017;130:1430-1440.
    PubMed     Abstract available

  486. MISHRA A, Porcu P
    Expanding and expounding the genomic map of CTCL.
    Blood. 2017;130:1389-1390.

  487. ROELENS M, Delord M, Ram-Wolff C, Marie-Cardine A, et al
    Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity.
    Blood. 2017;130:1468-1471.

  488. MALEK A, Bhagat G
    Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression.
    Blood. 2017;130:1388.

    Brentuximab: is it time for a new "B" in ABVD?
    Blood. 2017;130:1281-1282.

    High-risk DLBCL: interim PET? Not yet.
    Blood. 2017;130:1277-1278.

  491. MARTIN P, Ruan J, Leonard JP
    The potential for chemotherapy-free strategies in mantle cell lymphoma.
    Blood. 2017 Sep 12. pii: blood-2017-05-737510. doi: 10.1182/blood-2017-05-737510
    PubMed     Abstract available

  492. CAREY CD, Gusenleitner D, Lipschitz M, Roemer MGM, et al
    Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Blood. 2017 Sep 11. pii: blood-2017-03-770719. doi: 10.1182/blood-2017-03-770719
    PubMed     Abstract available

  493. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.

  494. TESSON B, Huet S, Grange B, Jallades L, et al
    Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes.
    Blood. 2017;130:1267-1269.

  495. MOSKOWITZ AJ, Schoder H, Gavane S, Thoren KL, et al
    Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877.
    PubMed     Abstract available

    August 2017
  496. KHODARAHMI I, Ghesani N
    Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Blood. 2017;130:1174.

  497. DAVIDS MS
    Targeting BCL-2 in B-cell lymphomas.
    Blood. 2017;130:1081-1088.
    PubMed     Abstract available

  498. KREMER KN, Dinkel BA, Sterner RM, Osborne DG, et al
    TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.
    Blood. 2017;130:982-994.
    PubMed     Abstract available

  499. ESKELUND CW, Dahl C, Hansen JW, Westman M, et al
    TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
    Blood. 2017 Aug 17. pii: blood-2017-04-779736. doi: 10.1182/blood-2017-04-779736
    PubMed     Abstract available

  500. LIN RJ, Behera M, Diefenbach CS, Flowers CR, et al
    The Role of Anthracycline and Comprehensive Geriatric Assessment for Elderly Patients with Diffuse Large B-cell Lymphoma.
    Blood. 2017 Aug 16. pii: blood-2017-05-736975. doi: 10.1182/blood-2017-05-736975

  501. BOUSKA A, Bi C, Lone W, Zhang W, et al
    Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
    Blood. 2017 Aug 11. pii: blood-2017-02-767335. doi: 10.1182/blood-2017-02-767335
    PubMed     Abstract available

  502. SALAR A, Domingo-Domenech E, Panizo C, Nicolas C, et al
    Long-term results of a phase II study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
    Blood. 2017 Aug 11. pii: blood-2017-07-795302. doi: 10.1182/blood-2017-07-795302

  503. OKONKWO L, Jaffe ES
    Intravascular large cell lymphoma of NK/T-cell type, EBV positive.
    Blood. 2017;130:837.

  504. NAM AS, Tam W
    An intrasinusoidal extracavitary variant of primary effusion lymphoma.
    Blood. 2017;130:836.

  505. WEIGERT O, Weinstock DM
    The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
    Blood. 2017 Aug 7. pii: blood-2017-07-737353. doi: 10.1182/blood-2017-07-737353.
    PubMed     Abstract available

  506. CRUMP M, Neelapu SS, Farooq U, Van Den Neste E, et al
    Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
    Blood. 2017 Aug 3. pii: blood-2017-03-769620. doi: 10.1182/blood-2017-03-769620.
    PubMed     Abstract available

  507. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Abstract available

    July 2017
  508. TSUYAMA N, Sakata S, Baba S, Mishima Y, et al
    BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
    Blood. 2017;130:489-500.
    PubMed     Abstract available

    SOX11 holds mantle cell lymphoma's key to home.
    Blood. 2017;130:389-391.

  510. EICHENAUER DA, Engert A
    R-CHOP in NLPHL: who should receive it?
    Blood. 2017;130:387-388.

  511. COURTOIS L, Sujobert P
    Morphologic features of mu-heavy-chain disease.
    Blood. 2017;130:558.

  512. CONNORS JM, Ansell SM, Fanale M, Park SI, et al
    Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma.
    Blood. 2017 Jul 21. pii: blood-2017-05-784678. doi: 10.1182/blood-2017-05-784678

  513. Predicting transformation of follicular lymphoma.
    Blood. 2017;130:383.

  514. GONG S, Hijiya N
    Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination.
    Blood. 2017;130:381.

    CD70 turns on NK cells to attack lymphoma.
    Blood. 2017;130:238-239.

  516. CABANILLAS F, Rivera N
    Check this checkpoint inhibitor in lymphoma.
    Blood. 2017;130:234-235.

  517. ERDMANN T, Klener P, Lynch JT, Grau M, et al
    Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Blood. 2017;130:310-322.
    PubMed     Abstract available

  518. THIEBLEMONT C, Cascione L, Conconi A, Kiesewetter B, et al
    A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial.
    Blood. 2017 Jul 18. pii: blood-2017-03-771915. doi: 10.1182/blood-2017-03-771915
    PubMed     Abstract available

  519. WOODS DM, Woan KV, Cheng F, Sodre AL, et al
    T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.
    Blood. 2017;130:146-155.
    PubMed     Abstract available

  520. CASASNOVAS RO, Ysebaert L, Thieblemont C, Bachy E, et al
    A FDG-PET driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase II study.
    Blood. 2017 Jul 12. pii: blood-2017-02-766691. doi: 10.1182/blood-2017-02-766691
    PubMed     Abstract available

  521. SZYDLOWSKI M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, et al
    Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Blood. 2017 Jul 11. pii: blood-2017-01-760702. doi: 10.1182/blood-2017-01-760702
    PubMed     Abstract available

    June 2017
  522. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.

  523. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Abstract available

  524. HAVRANEK O, Xu J, Kohrer S, Wang Z, et al
    Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-10-747303. doi: 10.1182/blood-2016-10-747303
    PubMed     Abstract available

  525. CHIN CK, Cheah CY
    How I treat patients with aggressive lymphoma at high risk of CNS relapse.
    Blood. 2017 Jun 13. pii: blood-2017-03-737460. doi: 10.1182/blood-2017-03-737460
    PubMed     Abstract available

    How I treat "Double Hit" lymphoma.
    Blood. 2017 Jun 9. pii: blood-2017-04-737320. doi: 10.1182/blood-2017-04-737320.
    PubMed     Abstract available

    Checkpoint inhibition in CNS lymphoma.
    Blood. 2017;129:3045-3046.

  528. ZHANG H, Chen Z, Miranda RN, Medeiros LJ, et al
    Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
    Blood. 2017 Jun 7. pii: blood-2017-02-767293. doi: 10.1182/blood-2017-02-767293.
    PubMed     Abstract available

    May 2017
  529. GILL K
    CD5-negative mantle cell lymphoma of the breast.
    Blood. 2017;129:2950.

  530. SCHMIDT J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, et al
    Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.
    Blood. 2017 May 22. pii: blood-2017-03-776278. doi: 10.1182/blood-2017-03-776278
    PubMed     Abstract available

  531. BALSAS P, Palomero J, Eguileor A, Rodriguez ML, et al
    SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
    Blood. 2017 May 22. pii: blood-2017-04-776740. doi: 10.1182/blood-2017-04-776740
    PubMed     Abstract available

  532. FANALE MA, Cheah CY, Rich A, Medeiros LJ, et al
    Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Blood. 2017 May 18. pii: blood-2017-02-766121. doi: 10.1182/blood-2017-02-766121
    PubMed     Abstract available

  533. PEDERSEN MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, et al
    DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.
    Blood. 2017 May 18. pii: blood-2016-12-755496. doi: 10.1182/blood-2016-12-755496

  534. GAY C, Delarue R, Milpied N, Oberic L, et al
    Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.
    Blood. 2017;129:2811-2813.

  535. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Abstract available

  536. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.

  537. TOUT M, Casasnovas O, Meignan M, Lamy T, et al
    Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
    Blood. 2017;129:2616-2623.
    PubMed     Abstract available

  538. ZINZANI PL, Ribrag V, Moskowitz CH, Michot JM, et al
    Safety & tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
    Blood. 2017 May 10. pii: blood-2016-12-758383. doi: 10.1182/blood-2016-12-758383
    PubMed     Abstract available

  539. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.

  540. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.

  541. HAVERKOS BM, Abbott D, Hamadani M, Armand P, et al
    PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346.
    PubMed     Abstract available

  542. KURUVILLA J, Savona M, Baz R, Mau-Sorensen M, et al
    Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma.
    Blood. 2017 May 3. pii: blood-2016-11-750174. doi: 10.1182/blood-2016-11-750174.
    PubMed     Abstract available

    April 2017
  543. JACCARD A, Hermine O
    A major turning point in NK/T-cell lymphoma?
    Blood. 2017;129:2342-2343.

  544. BUJISIC B, De Gassart A, Tallant R, Demaria O, et al
    Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Blood. 2017;129:2420-2428.
    PubMed     Abstract available

  545. CHIECCHIO L, Cullis JO
    De novo Richter transformation.
    Blood. 2017;129:2455.

  546. Risk of heart failure following Hodgkin lymphoma.
    Blood. 2017;129:2334.

  547. BHATT S, Parvin S, Zhang Y, Cho HM, et al
    Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Blood. 2017;129:2246-2256.
    PubMed     Abstract available

  548. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Abstract available

  549. LE GOUILL S, Casasnovas RO
    Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?
    Blood. 2017 Apr 17. pii: blood-2016-05-672196. doi: 10.1182/blood-2016-05-672196
    PubMed     Abstract available

  550. KRIDEL R, Sehn LH, Gascoyne RD
    Can histologic transformation of follicular lymphoma be predicted and prevented?
    Blood. 2017 Apr 13. pii: blood-2017-03-691345. doi: 10.1182/blood-2017-03-691345
    PubMed     Abstract available

  551. MILLER HK, Santo L, Camargo MC, Winkler CA, et al
    Coxiella burnetii antibody seropositivity is not a risk factor for AIDS-related non-Hodgkin lymphoma.
    Blood. 2017 Apr 10. pii: blood-2016-12-756569. doi: 10.1182/blood-2016-12-756569

  552. KAKKASSERY V, Schroers R, Coupland SE, Wunderlich MI, et al
    Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma.
    Blood. 2017 Apr 7. pii: blood-2017-01-765180. doi: 10.1182/blood-2017-01-765180.

    March 2017
  553. KAWASAKI K, Karube K
    Peripheral T-cell lymphoma with EBV-infected "anaplastic" B-cell proliferation confined to sinuses.
    Blood. 2017;129:1885.

  554. ALINARI L
    Toward autophagy-targeted therapy in lymphoma.
    Blood. 2017;129:1740-1742.

  555. NAYAK L, Iwamoto FM, LaCasce A, Mukundan S, et al
    PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Blood. 2017 Mar 29. pii: blood-2017-01-764209. doi: 10.1182/blood-2017-01-764209
    PubMed     Abstract available

  556. ENNISHI D, Mottok A, Ben-Neriah S, Shulha HP, et al
    Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact.
    Blood. 2017 Mar 28. pii: blood-2016-11-747022. doi: 10.1182/blood-2016-11-747022
    PubMed     Abstract available

  557. GOPAL AK, Kahl BS, Flowers CR, Martin P, et al
    Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Blood. 2017 Mar 21. pii: blood-2016-12-757740. doi: 10.1182/blood-2016-12-757740

  558. JAHN L, Hombrink P, Hagedoorn RS, Kester MG, et al
    TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
    Blood. 2017;129:1284-1295.
    PubMed     Abstract available

  559. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.

    February 2017
  560. CHONG EA, Melenhorst JJ, Lacey SF, Ambrose DE, et al
    PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
    Blood. 2017;129:1039-1041.

  561. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Abstract available

    January 2017
    Recurrent mutations and targeted therapy in FL.
    Blood. 2017;129:402-403.

  563. SESQUES P, Johnson NA
    Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Blood. 2017;129:280-288.
    PubMed     Abstract available

  564. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Abstract available

  565. YAHALOM J
    Curative radiation for orbital MZL: how much?
    Blood. 2017;129:270-271.

  566. KUO SH, Chen LT, Lin CW, Yeh KH, et al
    Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.
    Blood. 2017;129:188-198.
    PubMed     Abstract available

  567. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.

  568. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.

  569. STEIDL C
    Exposing Hodgkin-Reed-Sternberg cells.
    Blood. 2017;129:6-7.

    December 2016
  570. HUANG Q
    A striking bone marrow dyserythropoietic change but no anemia.
    Blood. 2016;128:3177.

  571. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Abstract available

    November 2016
  572. VILLA D
    Novel antivirals for HCV-associated lymphomas.
    Blood. 2016;128:2482-2483.

    September 2016
  573. ARCAINI L, Besson C, Frigeni M, Fontaine H, et al
    Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Blood. 2016 Sep 7. pii: blood-2016-05-714667.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.